Aviva PLC Has $51.04 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Aviva PLC boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 23.6% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 123,441 shares of the company's stock after purchasing an additional 23,542 shares during the period. Aviva PLC owned about 0.15% of IDEXX Laboratories worth $51,035,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Cranbrook Wealth Management LLC increased its holdings in IDEXX Laboratories by 7.0% in the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after buying an additional 25 shares during the last quarter. Perigon Wealth Management LLC grew its position in IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock worth $632,000 after acquiring an additional 26 shares in the last quarter. Summit Trail Advisors LLC increased its stake in shares of IDEXX Laboratories by 3.3% during the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after purchasing an additional 26 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of IDEXX Laboratories by 3.6% during the 4th quarter. IFP Advisors Inc now owns 903 shares of the company's stock valued at $373,000 after purchasing an additional 31 shares in the last quarter. Finally, Cape Cod Five Cents Savings Bank lifted its stake in shares of IDEXX Laboratories by 0.5% in the 3rd quarter. Cape Cod Five Cents Savings Bank now owns 6,344 shares of the company's stock valued at $3,091,000 after purchasing an additional 32 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX traded up $3.57 during trading hours on Friday, reaching $385.40. The stock had a trading volume of 370,567 shares, compared to its average volume of 611,801. The business's fifty day moving average is $429.51 and its two-hundred day moving average is $434.87. The company has a market cap of $31.23 billion, a price-to-earnings ratio of 36.07, a PEG ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Insider Activity at IDEXX Laboratories

In related news, Director M Anne Szostak sold 3,000 shares of the business's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. The trade was a 49.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have commented on IDXX. Barclays increased their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Bank of America raised their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research note on Tuesday, February 4th. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, April 4th. Piper Sandler lifted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Finally, Morgan Stanley decreased their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.